Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.60 |
| ▸ | REN | P00797 | 4/20 | 0.57 |
| ▸ | LTA4H | P09960 | 1/20 | 0.55 |
| ▸ | MMP2 | P08253 | 1/20 | 0.55 |
| ▸ | MMP7 | P09237 | 1/20 | 0.55 |
| ▸ | MMP9 | P14780 | 1/20 | 0.55 |
| ▸ | MMP12 | P39900 | 1/20 | 0.55 |
| ▸ | MMP13 | P45452 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8060317 | 0.96 | MME (0.59) | MMERENLTA4HMMP2MMP7 | |
| SCHEMBL8060325 | 0.96 | MME (0.59) | MMERENLTA4HMMP2MMP7 | |
| SCHEMBL29427560 | 0.95 | MME (0.58) | MMERENLTA4HMMP2MMP7 | |
| SCHEMBL9551455 | 0.94 | MME (0.64) | MMELTA4HMMP2MMP7MMP9 | |
| SCHEMBL9829182 | 0.94 | MME (0.64) | MMELTA4HMMP2MMP7MMP9 | |
| SCHEMBL5370772 | 0.94 | MME (0.64) | MMELTA4HMMP2MMP7MMP9 | |
| SCHEMBL29746506 | 0.92 | OPRM1 (0.60) | MMERENOPRM1OPRD1OPRK1 | |
| SCHEMBL21192616 | 0.92 | ACE (0.57) | MMERENMMP2MMP7MMP9 | |
| SCHEMBL21192611 | 0.92 | ACE (0.57) | MMERENMMP2MMP7MMP9 | |
| SCHEMBL29966332 | 0.91 | REN (0.57) | MMERENOPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116985-A1 | STAPLED PEPTIDES AND METHODS THEREOF | PARABILIS MEDICINES, INC. | 2024-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116985-A1 | STAPLED PEPTIDES AND METHODS THEREOF | CTNNB1, APC, CTNNA1 | MME 467/4885REN 818/4885LTA4H 4132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.